HAE Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
Haemonetics Corp is not a strong buy for a beginner long-term investor at this time. The stock is currently in a bearish technical trend, with oversold indicators but no clear reversal signals. While financial performance shows some positive trends in net income and EPS, revenue has declined, and recent news indicates a lack of confidence from institutional investors. Analysts have mixed ratings, with some lowering price targets. Given the investor's long-term focus and the lack of strong positive catalysts, it is better to hold off on buying until clearer signs of recovery emerge.
The stock is in a bearish trend with MACD below zero and negatively expanding, RSI at 9.42 indicating oversold conditions, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). Key support is at 55.902, and resistance is at 58.123. The stock is trading near support but lacks a reversal signal.
Analysts from Barrington and Mizuho maintain an Outperform rating despite lowering price targets.
Invenomic Capital Management fully exited its position, signaling a lack of confidence. The stock has declined 9% over the past year, and technical indicators show bearish momentum.
In Q3 2026, revenue dropped to $338.97 million (-2.75% YoY), but net income increased to $44.74 million (+19.33% YoY), EPS rose to 0.95 (+28.38% YoY), and gross margin improved to 56.47% (+6.77% YoY).
Analysts have mixed views. Citi lowered the price target to $70 and maintains a Neutral rating, while Mizuho and Barrington lowered price targets but maintain Outperform ratings. Recent adjustments reflect cautious optimism but no strong buy signals.
